Welcome to our dedicated page for Connect Biopharma Holdings SEC filings (Ticker: CNTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Connect Biopharma Holdings Limited filings document regulatory disclosures for a Cayman Islands clinical-stage biopharmaceutical issuer developing rademikibart for inflammatory diseases. Recent Form 8-K reports cover operating and financial results, clinical and regulatory updates tied to rademikibart, and Regulation FD disclosures.
The filing record also includes governance and capital-structure matters, including board composition, insider purchase disclosures, material agreements, ADR-program and deposit-agreement disclosures, and the relationship between American depositary shares and ordinary shares. These filings frame the company’s emerging-growth-company status, public-company reporting obligations and risk-related clinical development disclosures.
Connect Biopharma Holdings Ltd executive Lisa Peraza, Senior Vice President of Finance, filed an initial ownership report showing her equity position in the company. She directly holds 45,189 Ordinary Shares.
She also holds several employee stock options over Ordinary Shares, including 400,000 shares at $1.15 per share expiring on August 12, 2034, 55,318 shares at $0.97 expiring on December 26, 2034, 40,000 shares at $1.14 expiring on July 7, 2035, and 250,000 shares at $2.69 expiring on December 26, 2035. Footnotes state these options generally vest over four years, with either a 25% cliff after one year followed by monthly vesting, or monthly vesting over four years, in each case requiring continued service.
Connect Biopharma Holdings Ltd director Kleanthis Gabriel Xanthopoulos filed an initial statement of beneficial ownership. He reports holding 80,000 Ordinary Shares directly, plus several stock options to buy Ordinary Shares with exercise prices between $0.96 and $8.16, expiring from 2030 to 2036. One option series is fully vested and exercisable, while another fully vests and becomes exercisable on March 2, 2027.
Connect Biopharma Holdings Ltd director Karen J. Wilson reported her equity holdings in the company. The filing lists stock options over multiple blocks of Ordinary Shares, including rights to buy 89,220 shares at an exercise price of $8.1600 per share expiring on November 1, 2030, alongside additional options at exercise prices of $4.1200, $1.2700, $1.1800, $0.9600, and $2.5000 with expirations between March 1, 2032 and March 2, 2036. She also directly holds 10,000 Ordinary Shares. Footnotes state that one option grant is fully vested and exercisable, and another will fully vest and become exercisable on March 2, 2027.
Connect Biopharma Holdings Ltd director James A. Schoeneck reported his initial beneficial ownership of stock options. He holds options to purchase 120,000 ordinary shares at an exercise price of $2.38 per share, expiring on July 22, 2035, which vest over three years.
He also holds options to purchase 60,000 ordinary shares at an exercise price of $2.50 per share, expiring on March 2, 2036, which fully vest on March 2, 2027. The filing lists these derivative holdings and does not show any buy or sell transactions.
Connect Biopharma Holdings Ltd director Jean I Liu filed an initial ownership report detailing several stock options over Ordinary Shares. The options have exercise prices that include $22.29, $4.12, $1.27, $1.18, $0.96 and $2.50, with expiration dates ranging from 2031 through 2036.
The filing notes that one stock option is already fully vested and exercisable, while another will fully vest and become exercisable on March 2, 2027. The report lists holdings only and does not show any purchases or sales.
Connect Biopharma Holdings Ltd filing reports that BioFortune Inc. and Wubin Pan reported beneficial ownership of Ordinary Shares as of December 31, 2025. The filing shows 5,987,431 shares held of record by BioFortune Inc. (representing 10.7% of the class) and 6,026,813 shares attributable to Wubin Pan (representing 10.8% of the class), based on 55,903,513 Ordinary Shares outstanding as of October 31, 2025. The statement discloses that Mr. Pan is the sole shareholder of BioFortune Inc. and therefore shares beneficial ownership of the shares held by that entity; shared voting and dispositive power amounts are provided in the filing.
Connect Biopharma Holdings Ltd — Amendment to a Schedule 13G filing reporting that Zheng Wei beneficially owns 5,015,960 Ordinary Shares, representing 9.0% of the class as of December 31, 2025.
Shares outstanding were 55,903,513 Ordinary Shares as of October 31, 2025, provided as context from the issuer's Form 10-Q.
Ikarian Capital, LLC and Neil Shahrestani have disclosed an 8.8% passive stake in Connect Biopharma Holdings Limited. They report beneficial ownership of 4,933,086 ordinary shares, including 144,600 shares that can be acquired within 60 days through call options, based on 55,903,513 shares outstanding as of October 31, 2025.
The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts for which Ikarian Capital acts as investment manager or sub-adviser. The filers certify the position is held in the ordinary course of business and state it was not acquired to change or influence control of Connect Biopharma.
Connect Biopharma (CNTB) reported Q3 2025 results with license and collaboration revenue of $16,000 and total operating expenses of $17.7 million, driven by research and development of $11.1 million and general and administrative of $6.6 million. The company posted a net loss of $17.2 million (basic and diluted loss per share $0.31). For the nine months, revenue was $64,000 and net loss was $40.4 million.
Cash, cash equivalents and short-term investments were $54.8 million as of September 30, 2025. Management believes these resources will fund anticipated needs for at least one year from the filing date. Total shareholders’ equity was $55.4 million.
In September, CNTB terminated its ADR program; ADRs were exchanged one-for-one into ordinary shares, which now trade on Nasdaq under “CNTB.” The company presented rademikibart data at ERS 2025 and is running Phase 2 studies in acute exacerbations of asthma and COPD, with topline data expected in the first half of 2026. As of October 31, 2025, 55,903,513 ordinary shares were outstanding.
Connect Biopharma Holdings Limited filed an 8-K stating it issued a press release announcing financial results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.
Per Item 2.02 and General Instruction B.2, the information, including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act. The company’s ordinary shares trade on the Nasdaq Global Market under the symbol CNTB.